Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 10:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,087 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Lung Diseases Clear all
Active, not recruiting Phase 2Phase 3 Interventional

Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis

NCT04948203
View directory record Official record
Conditions
Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
Interventions
Sirolimus
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 2 Interventional

Effect of Ventilation-Feedback Training on Exercise Performance in COPD

NCT00037973
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ventilation feedback, exercise
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 15, 2010 · Synced Sep 22, 2026, 10:05 PM EDT
Terminated Not applicable Interventional

Impact of Non-invasive Ventilation in Hypercapnic COPD

NCT03522805
View directory record Official record
Conditions
Copd, Chronic Obstructive Pulmonary Disease, Hypercapnia, Chronic Respiratory Failure, Hypoventilation
Interventions
High-intensity non-invasive ventilation
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
45 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 4 Interventional Results available

Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.

NCT01323673
View directory record Official record
Conditions
Dermatitis, Chronic
Interventions
clobetasol propionate 0.05%, Vehicle / Placebo
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
San Diego, California • Boynton Beach, Florida • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Not applicable Interventional

Homing in on Health: Study of a Home Delivered Chronic Disease Self Management Program

NCT00263939
View directory record Official record
Conditions
Diabetes Mellitus, Congestive Heart Failure, Arthritis, COPD, Depression
Interventions
Homing in on Health
Behavioral
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
40 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD

NCT02347761
View directory record Official record
Conditions
COPD
Interventions
SUN-101 50 mcg BID eFlow (CS) nebulizer, SUN-101 25 mcg BID eFlow (CS) nebulizer, Placebo BID eFlow Closed System (CS) nebulizer
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
44
States / cities
Anniston, Alabama • Phoenix, Arizona • Tempe, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 22, 2026, 10:05 PM EDT
Enrolling by invitation Phase 2 Interventional

Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

NCT06751602
View directory record Official record
Conditions
Rejection Chronic Renal
Interventions
Belumosudil 200 mg QD, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Tiotropium Bromide Inhalation Powder

NCT05161156
View directory record Official record
Conditions
COPD
Interventions
Test Product (tiotropium bromide inhalation powder), 18 mcg of Spiriva (Reference Product), Placebo
Combination Product
Lead sponsor
Phargentis SA
Industry
Eligibility
40 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Anderson, South Carolina • Gaffney, South Carolina • Union, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 3 Interventional

Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)

NCT00103922
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
cilomilast
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
115
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 22, 2026, 10:05 PM EDT
Not listed Not applicable Interventional

Team-based Versus Primary Care Clinician-led Advance Care Planning in Practice-based Research Networks

NCT03577002
View directory record Official record
Conditions
Congestive Heart Failure, Cancer, Chronic Obstructive Pulmonary Disease, Cerebrovascular Accident, Frail Elderly Syndrome, Cardiovascular Diseases
Interventions
Serious Illness Care Program (SICP)
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
1,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Aurora, Colorado • Iowa City, Iowa • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma

NCT01199289
View directory record Official record
Conditions
Asthma
Interventions
AMG 827, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Encinitas, California • Huntington Beach, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 22, 2026, 10:05 PM EDT
Completed No phase listed Observational

Symptom Tracking in Long COVID Patients Using Formula C™ Sublingual Drops

NCT06163690
View directory record Official record
Conditions
Long COVID, Long Covid19, Post-Acute COVID-19, Post-Acute COVID-19 Syndrome, Long Haul COVID, Long-Haul COVID-19
Interventions
Endourage Targeted Wellness Formula C™, a full hemp flower extract
Combination Product
Lead sponsor
Endourage, LLC
Industry
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 22, 2026, 10:05 PM EDT
Recruiting Not applicable Interventional

Inter-lobar Fissure Completion in Patients With Failed Bronchoscopic Lung Volume Reduction

NCT05257681
View directory record Official record
Conditions
Emphysema or COPD
Interventions
Interlobar fissure completion and pleural adhesiolysis
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Completed No phase listed Observational

Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation

NCT07414134
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
BGF- BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
3,598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Gaithersburg, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 3 Interventional

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

NCT05742802
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tozorakimab 1, Tozorakimab 2, Placebo
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
1,713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
46
States / cities
Sheffield, Alabama • Tempe, Arizona • Lincoln, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Terminated Phase 2 Interventional

A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)

NCT01064037
View directory record Official record
Conditions
Heart Failure, Heart Decompensation
Interventions
Cinaciguat (BAY58-2667), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Chicago, Illinois • Detroit, Michigan • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 4 Interventional

Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease

NCT00316992
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ramelteon and Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
40 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2010 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

Residential Cleaning of Indoor Air to Protect COPD Patients

NCT03750292
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
HEPAirX air filter, control air filter
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 2 Interventional

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

NCT01321463
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
PH-797804, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 80 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
22
States / cities
Mobile, Alabama • Glendale, Arizona • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Sep 22, 2026, 10:05 PM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT03345407
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Reducing Dynamic Hyperinflation Through Breathing Retraining

NCT01009099
View directory record Official record
Conditions
Pulmonary Disease, COPD
Interventions
breathing retraining, exercise training
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years to 85 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2015 · Synced Sep 22, 2026, 10:05 PM EDT
Recruiting Not applicable Interventional

MoblO2 to Maintain Oxygenation

NCT07704567
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease), Intersitital Lung Disease
Interventions
MoblO2 controls O2 flow, MoblO2 does not control flow
Other
Lead sponsor
Minnesota HealthSolutions
Industry
Eligibility
25 Years to 95 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

NCT03059992
View directory record Official record
Conditions
Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi
Interventions
Ibrexafungerp
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

Advance Care Planning in the Emergency Department

NCT05209880
View directory record Official record
Conditions
Congestive Heart Failure, Metastatic Cancer, Chronic Kidney Disease Requiring Chronic Dialysis, Chronic Obstructive Pulmonary Disease
Interventions
ED GOAL
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 22, 2026, 10:05 PM EDT